Journal of International Oncology››2023,Vol. 50››Issue (12): 766-768.doi:10.3760/cma.j.cn371439-20230220-00144
Received:2023-02-20Revised:2023-09-21Online:2023-12-08Published:2024-01-16
"
"
"
"
"
| [1] | Song Z, Zou K, Zou L. Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: an update on clinical data[J].Front Oncol,2022,12: 1045481. DOI:10.3389/fonc.2022.1045481. |
| [2] | Gennigens C, Jerusalem G, Lapaille L, et al. Recurrent or primary metastatic cervical cancer: current and future treatments[J].ESMO Open,2022,7(5): 100579. DOI:10.1016/j.esmoop.2022.100579. |
| [3] | 李英, 程忠平. 复发性宫颈癌免疫治疗的研究进展[J].中国妇产科临床杂志,2023,24(1): 108-110. DOI:10.13390/j.issn.1672-1861.2023.01.041. |
| [4] | 孙敬兰, 戴建荣. 宫颈癌免疫治疗的临床研究进展[J].医学综述,2022,28(16): 3204-3210. |
| [5] | Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 pathway from discovery to clinical implementation[J].Front Immunol,2016,7: 550. DOI:10.3389/fimmu.2016.00550. |
| [6] | Bevins NJ, Okamura R, Montesion M, et al. Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1/PD-L1 immunotherapy[J].J Immunother Precis Oncol,2022,5(4): 90-97. DOI:10.36401/JIPO-22-9. pmid:36483582 |
| [7] | Wang LL, Li ZH, Hu XH, et al. The roles of the PD-1/PD-L1 pathway at immunologically privileged sites[J].Am J Reprod Immunol,2017,78(2): 12710. DOI:10.1111/aji.12710. |
| [8] | Li W, Wu F, Zhao S, et al. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: a key player in tumor immunotherapy[J].Cytokine Growth Factor Rev,2022,67: 49-57. DOI:10.1016/j.cytogfr.2022.07.004. |
| [9] | Yang Y, Wang X, Bai Y, et al. Programmed death-ligand 2 (PD-L2) expression in bladder cancer[J].Urol Oncol,2020,38(6): 603.e9-603.e15. DOI:10.1016/j.urolonc.2020.01.001. |
| [10] | Rotman J, den Otter LAS, Bleeker MCG, et al. PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential[J].Front Immunol,2020,11: 596825. DOI:10.3389/fimmu.2020.596825. |
| [11] | Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J].Lancet,2018,392(10142): 123-133. DOI:10.1016/S0140-6736(18)31257-1. pmid:29880231 |
| [12] | Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J].J Clin Oncol,2019,37(17): 1470-1478. DOI:10.1200/JCO.18.01265. |
| [13] | 杨钧媛, 蔡红兵. 宫颈癌免疫治疗的耐药机制及应对措施[J].肿瘤防治研究,2022,49(9): 886-892. DOI:10.3971/j.issn.1000-8578.2022.22.0162. |
| [14] | Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy[J].Annu Rev Immunol,2022,40: 45-74. DOI:10.1146/annurev-immunol-070621-030155. pmid:35471840 |
| [15] | O'Malley DM, Neffa M, Monk BJ, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase Ⅱ study[J].J Clin Oncol,2022,40(7): 762-771. DOI:10.1200/JCO.21.02067. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
